Delivery Order SPE2DB22D1002-SPE2DB25FLFG3
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Dupixent 300 mg/2 mL syringes with a ceiling value of $6,837.84. This non-set-aside, firm fixed price delivery order is scheduled for completion by July 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a continuation of the company's ongoing pharmaceutical supply support to federal...
- The Defense Logistics Agency awarded a delivery order valued at $1,709.46 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml syringes on July 21, 2025. This firm fixed-price, non-set-aside delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. The contract was...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Dupixent 300 mg/2 ml syringes. The contract is a firm-fixed-price delivery order with a ceiling value of $16,414.50 and a completion date of September 10, 2024. AmerisourceBergen, through its Corporate Office division, has been awarded this contract to provide the medication to support military treatment facilities and other federal...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml syringes with a ceiling value of $47,754.38. This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for ultimate completion by July 21, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill the order from its corporate office location. This delivery order is issued under...
- The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract valued at $24,419.18 to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Dupixent 300 mg/2 ml syringes and has a completion date of February 3, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through...
- The Defense Logistics Agency awarded a $4.5K delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for Dupixent 300 mg/2 mL syringes. This non-set-aside contract utilizes firm fixed pricing and requires performance completion by July 22, 2025. The award represents a delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $1 billion ceiling value and extends through December 2026. This...
- The Defense Logistics Agency awarded a $41,453.26 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent 300 mg/2 ml pens. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to the company's corporate office location in...
- This is a $18,876.59 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Dupixent 300 mg/2 mL syringes, with a completion date of February 12, 2025. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which provides a comprehensive range of...
- The Defense Logistics Agency awarded a delivery order valued at $10,777.92 to AmerisourceBergen Drug Corp for the supply of Dupixent (dupilumab) 300 mg/2 mL syringes on July 18, 2025, with completion scheduled for July 21, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania,...
- This is a $11,378.58 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Dupixent 300 mg/2 ml syringes. The contract has an ultimate completion date of July 8, 2025 and is not a set-aside. AmerisourceBergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a comprehensive global pharmaceutical support vehicle...
- SPE2DB22D1002Indefinite Delivery Contract
- SPE2DB22D1002-SPE2DB25FLFG3Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dupixent 300 mg/2 mL syringes valued at $4,991.39. This non-set-aside, firm fixed-price delivery order is scheduled for completion by July 28, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The award represents a discrete purchase under AmerisourceBergen's existing contract vehicle with the DLA. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that serves as a critical federal vendor for medical procurement, particularly supporting military and veteran healthcare systems. This delivery order is a child contract issued under the company's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. This prime contract vehicle enables AmerisourceBergen to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally, including specialty medications, brand-name and generic drugs, and medical devices across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.0k | 7/25/25 |